Background Bladder cancer, the ninth-most-common malignancy worldwide with an
estimated 356,000 new cases and 145,000 deaths annually, has a propensity to relapse …

Colorectal cancer (CRC), which is notorious for high morbidity and mortality around the
world, shows a predilection for metastasis to liver. Interleukin-8 (IL-8), a chemokine with a …

This study investigated the effects of microRNA-135a (miR-135a) targeting of glycogen
synthase kinase 3β (GSK3β) on the epithelial–mesenchymal transition (EMT), migration and …

Interleukin-17 (IL-17) has been shown to promote development of prostate, colon, skin, lung,
breast, and pancreatic cancer. The purpose of this study was to determine if IL-17 regulates …

Inflammation contributes to the development and progression of cancer. Interleukin-17 (IL-
17) is an inflammatory cytokine that functions in inflammation and cancer, as well as several …

Various survival factors such as the pleiotropic cytokine interleukin-6 (IL-6), a major mediator
of inflammation and activator of signal transducer and activator of transcription 3 (STAT3) …

Background The new modalities for treating patients with non-muscle invasive bladder
cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated …

BACKGROUND A number of recent studies have identified interleukin (IL)‐6 as an important
regulator of prostate cancer growth. Here, we investigate the potential interaction of IL‐6 with …

Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …

Breakdown of the extracellular matrix (ECM) is accomplished by the concerted action of
several proteases, including the urokinase plasminogen-activator (uPA) system and matrix …